Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes

One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.